One Probe Spanning Optical Imaging, X-rays, and MRI: Lanthanide Carriers Move Toward Integrated Diagnosis and Treatment

Medical imaging often requires trade-offs among penetration depth, resolution, sensitivity, and safety. A peer-reviewed review published in *Frontiers in Science* notes that placing lanthanide ions such as lanthanum, europium, terbium, and gadolinium in suitable nanoparticles, organic complexes, or protein carriers may make it possible to tune their luminescent and magnetic properties, enabling the same class of materials to span near-infrared optical imaging, X-rays, and magnetic resonance imaging (MRI), and even serve as drug-delivery tools.

The distinctive properties of lanthanide elements arise from their electronic structures: narrow emission bands, long signal lifetimes, and resistance to photobleaching, while some ions also exhibit strong paramagnetism. Carriers stabilize the metal ions, improve water solubility and biocompatibility, and can be functionalized with molecules that recognize tumors or other biomarkers. On this basis, research teams are developing deep-tissue and multiplex imaging to distinguish different targets within a single image while reducing background signals and light-induced tissue damage.

Each imaging modality offers a different point of entry. In near-infrared imaging, lanthanide nanoprobe signals can be encoded through color, brightness, or luminescence lifetime to track intracellular particles and physiological changes. For X-ray applications, the high atomic numbers of lanthanide elements facilitate X-ray absorption and also allow radiation to be converted into detectable optical signals; research directions include low-dose, low-background diagnostic imaging. Gadolinium ions and lanthanide-binding proteins are also being explored as MRI contrast agents, with the aim of improving relaxivity, tissue targeting, and renal clearance.

These materials are also gradually moving from “seeing lesions” toward integrated diagnosis and treatment. Once their surfaces are functionalized with targeting molecules or stimulus-responsive components, carriers can deliver drugs while locating lesions, with imaging used to monitor distribution or treatment response. However, a concurrent commentary cautions that more functions do not necessarily mean greater clinical value. Every added imaging, sensing, or therapeutic function increases the complexity of synthesis, batch reproducibility, toxicology, and regulatory review. The key question remains whether the combined approach can answer a clinical question that a single modality cannot.

Artificial intelligence has two more concrete uses in this blueprint: extracting quantifiable indicators from complex optical or magnetic signals, and helping search for material formulations, surface structures, and probe designs. However, the article is a review of the field, not a performance trial of a new probe or clinical algorithm, and it provides no clinical data that directly demonstrate diagnostic accuracy or patient benefit. In biological environments, pH, viscosity, protein adsorption, and particle aggregation may also alter readouts, causing algorithms to misinterpret changes in materials or the environment as disease signals.

A concurrent perspective therefore advocates using in situ calibration, independent measurement methods, comprehensive error analysis, and transparent disclosure of imaging conditions to test whether probes are truly reliable. A policy analysis further recommends that when clinical values depend on algorithmic interpretation, the imaging agent and software should be treated as an integrated measurement system and validated using shared reference standards, physical or digital phantoms, organoids, and organs-on-chips. Whole-body distribution, retention, and elimination must still be addressed through whole-organism studies, and algorithm drift must be monitored after software deployment.

The greatest unknown in clinical translation remains what happens after the material leaves the scan image. Whether carriers degrade and release free metal ions, which organs accumulate the particles, and whether the materials can be manufactured reliably at scale while maintaining batch consistency all require long-term data. Existing results largely remain at the proof-of-concept or preclinical stage. In the near term, lanthanide carriers are more likely to first find a place in applications where existing probes are inadequate, such as multiplex, deep-tissue, or functional imaging, rather than comprehensively replacing clinical imaging agents for which safety and manufacturing have already been standardized.